한글목차

개요

원발성 담즙성 담관염 치료제 시장은 2023-20281년에 3억 4,685만 달러, 예측 기간 중 CAGR은 8.75%로 성장할 것으로 예측됩니다.

원발성 담즙성 담관염 치료제 시장의 전체적인 분석, 시장 규모·예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 다룬 벤더 분석 등을 제공합니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 시장은 원격의료와 원격 모니터링의 출현, 헬스케어 산업에서의 투자와 개발의 증가, 원발성 담즙성 담관염 치료제 시장에서 제품 발매의 증가에 의해 촉진되고 있습니다.

본 조사에서는 향후 수년간 원발성 담즙성 담관염 치료제 시장 성장을 촉진하는 주요 요인으로 정부 헬스케어 지출에 의한 연구개발의 수요 증가를 들고 있습니다. 또한 노년 인구의 증가 및 제조업체에 의한 원발성 담즙성 담관염 치료제에 대한 연구개발 투자의 증가도 시장의 큰 수요로 연결됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 에코시스템

제3장 시장 규모 파악

• 시장의 정의
• 시장 부문 분석
• 시장 규모 2023
• 시장 전망 2023-2028

제4장 시장 규모 실적

• 세계의 원발성 담즙성 담관염 치료제 시장 2018-2022
• 유형 부문 분석 2018-2022
• 유통 채널 부문 분석 2018-2022
• 지역별 부문 분석 2018-2022
• 국가별 부문 분석 2018-2022

제5장 Five forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 현황

제6장 시장 세분화 : 유형별

• 시장 부문
• 비교 : 유형별
• 1차 약제 : 시장 규모와 예측 2023-2028
• 2차 약제 : 시장 규모와 예측 2023-2028
• 시장 기회 : 유형별

제7장 시장 세분화 : 유통 채널별

• 시장 부문
• 비교 : 유통 채널별
• 드러그스토어 및 소매 약국 : 시장 규모와 예측 2023-2028
• 병원 약국 : 시장 규모와 예측 2023-2028
• 온라인 약국 : 시장 규모와 예측 2023-2028
• 시장 기회 : 유통 채널별

제8장 고객 상황

• 고객 상황의 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측 2023-2028
• 유럽 : 시장 규모와 예측 2023-2028
• 아시아 : 시장 규모와 예측 2023-2028
• 세계의 기타 지역 : 시장 규모와 예측 2023-2028
• 미국 : 시장 규모와 예측 2023-2028
• 캐나다 : 시장 규모와 예측 2023-2028
• 독일 : 시장 규모와 예측 2023-2028
• 중국 : 시장 규모와 예측 2023-2028
• 영국 : 시장 규모와 예측 2023-2028
• 시장 기회 : 지역 상황별

제10장 촉진요인, 과제 및 동향

• 시장 촉진요인
• 시장이 해결해야 할 과제
• 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란의 상황
• 업계의 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Abbott Laboratories
• AbbVie Inc.
• Alkem Laboratories Ltd.
• Eli Lilly and Co.
• GENFIT SA
• Glenmark Pharmaceuticals Ltd.
• ICE S.p.a.
• Intercept Pharmaceuticals Inc.
• Ipsen Pharma
• Leeford Healthcare Ltd.
• NGM Biopharmaceuticals Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd.

제13장 부록

영문목차

Abstract

The primary biliary cholangitis therapeutics market is forecasted to grow by USD 346.85 mn during 2023-2028, accelerating at a CAGR of 8.75% during the forecast period. The report on the primary biliary cholangitis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by emergence of telehealth and remote monitoring, rising investments and developments in healthcare industry, and increase in product launches in primary biliary cholangitis therapeutics market.

Technavio's primary biliary cholangitis therapeutics market is segmented as below:

By Type

• Primary drug
• Secondary drug

By Distribution Channel

• Drug stores and retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increasing demand for R&D due to government healthcare expenditure as one of the prime reasons driving the primary biliary cholangitis therapeutics market growth during the next few years. Also, increasing geriatric population and rise in the R and D investments in primary biliary cholangitis therapeutics by manufacturers will lead to sizable demand in the market.

The report on the primary biliary cholangitis therapeutics market covers the following areas:

• Primary biliary cholangitis therapeutics market sizing
• Primary biliary cholangitis therapeutics market forecast
• Primary biliary cholangitis therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary biliary cholangitis therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Eli Lilly and Co., GENFIT SA, Glenmark Pharmaceuticals Ltd., ICE S.p.a., Intercept Pharmaceuticals Inc., Ipsen Pharma, Leeford Healthcare Ltd., NGM Biopharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.. Also, the primary biliary cholangitis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global primary biliary cholangitis therapeutics market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global primary biliary cholangitis therapeutics market 2018 - 2022 ($ million)
• 4.2 Type Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
• 4.3 Distribution Channel Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

• 6.1 Market segments
• Exhibit 30: Chart on Type - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
• 6.2 Comparison by Type
• Exhibit 32: Chart on Comparison by Type
• Exhibit 33: Data Table on Comparison by Type
• 6.3 Primary drug - Market size and forecast 2023-2028
• Exhibit 34: Chart on Primary drug - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Primary drug - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Primary drug - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Primary drug - Year-over-year growth 2023-2028 (%)
• 6.4 Secondary drug - Market size and forecast 2023-2028
• Exhibit 38: Chart on Secondary drug - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Secondary drug - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Secondary drug - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Secondary drug - Year-over-year growth 2023-2028 (%)
• 6.5 Market opportunity by Type
• Exhibit 42: Market opportunity by Type ($ million)
• Exhibit 43: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
• 7.2 Comparison by Distribution Channel
• Exhibit 46: Chart on Comparison by Distribution Channel
• Exhibit 47: Data Table on Comparison by Distribution Channel
• 7.3 Drug stores and retail pharmacies - Market size and forecast 2023-2028
• Exhibit 48: Chart on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 49: Data Table on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 50: Chart on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 51: Data Table on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
• 7.4 Hospital pharmacies - Market size and forecast 2023-2028
• Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• 7.5 Online pharmacies - Market size and forecast 2023-2028
• Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Distribution Channel
• Exhibit 60: Market opportunity by Distribution Channel ($ million)
• Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Canada - Market size and forecast 2023-2028
• Exhibit 87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• 9.9 Germany - Market size and forecast 2023-2028
• Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.10 China - Market size and forecast 2023-2028
• Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.11 UK - Market size and forecast 2023-2028
• Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Abbott Laboratories
• Exhibit 111: Abbott Laboratories - Overview
• Exhibit 112: Abbott Laboratories - Business segments
• Exhibit 113: Abbott Laboratories - Key news
• Exhibit 114: Abbott Laboratories - Key offerings
• Exhibit 115: Abbott Laboratories - Segment focus
• 12.4 AbbVie Inc.
• Exhibit 116: AbbVie Inc. - Overview
• Exhibit 117: AbbVie Inc. - Product / Service
• Exhibit 118: AbbVie Inc. - Key news
• Exhibit 119: AbbVie Inc. - Key offerings
• 12.5 Alkem Laboratories Ltd.
• Exhibit 120: Alkem Laboratories Ltd. - Overview
• Exhibit 121: Alkem Laboratories Ltd. - Business segments
• Exhibit 122: Alkem Laboratories Ltd. - Key news
• Exhibit 123: Alkem Laboratories Ltd. - Key offerings
• Exhibit 124: Alkem Laboratories Ltd. - Segment focus
• 12.6 Eli Lilly and Co.
• Exhibit 125: Eli Lilly and Co. - Overview
• Exhibit 126: Eli Lilly and Co. - Product / Service
• Exhibit 127: Eli Lilly and Co. - Key news
• Exhibit 128: Eli Lilly and Co. - Key offerings
• 12.7 GENFIT SA
• Exhibit 129: GENFIT SA - Overview
• Exhibit 130: GENFIT SA - Product / Service
• Exhibit 131: GENFIT SA - Key offerings
• 12.8 Glenmark Pharmaceuticals Ltd.
• Exhibit 132: Glenmark Pharmaceuticals Ltd. - Overview
• Exhibit 133: Glenmark Pharmaceuticals Ltd. - Product / Service
• Exhibit 134: Glenmark Pharmaceuticals Ltd. - Key offerings
• 12.9 ICE S.p.a.
• Exhibit 135: ICE S.p.a. - Overview
• Exhibit 136: ICE S.p.a. - Product / Service
• Exhibit 137: ICE S.p.a. - Key offerings
• 12.10 Intercept Pharmaceuticals Inc.
• Exhibit 138: Intercept Pharmaceuticals Inc. - Overview
• Exhibit 139: Intercept Pharmaceuticals Inc. - Product / Service
• Exhibit 140: Intercept Pharmaceuticals Inc. - Key offerings
• 12.11 Ipsen Pharma
• Exhibit 141: Ipsen Pharma - Overview
• Exhibit 142: Ipsen Pharma - Business segments
• Exhibit 143: Ipsen Pharma - Key offerings
• Exhibit 144: Ipsen Pharma - Segment focus
• 12.12 Leeford Healthcare Ltd.
• Exhibit 145: Leeford Healthcare Ltd. - Overview
• Exhibit 146: Leeford Healthcare Ltd. - Key offerings
• 12.13 NGM Biopharmaceuticals Inc.
• Exhibit 147: NGM Biopharmaceuticals Inc. - Overview
• Exhibit 148: NGM Biopharmaceuticals Inc. - Key offerings
• 12.14 Novartis AG
• Exhibit 149: Novartis AG - Overview
• Exhibit 150: Novartis AG - Business segments
• Exhibit 151: Novartis AG - Key offerings
• Exhibit 152: Novartis AG - Segment focus
• 12.15 Teva Pharmaceutical Industries Ltd.
• Exhibit 153: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 154: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 155: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 156: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 157: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.16 Viatris Inc.
• Exhibit 158: Viatris Inc. - Overview
• Exhibit 159: Viatris Inc. - Business segments
• Exhibit 160: Viatris Inc. - Key news
• Exhibit 161: Viatris Inc. - Key offerings
• Exhibit 162: Viatris Inc. - Segment focus
• 12.17 Zydus Lifesciences Ltd.
• Exhibit 163: Zydus Lifesciences Ltd. - Overview
• Exhibit 164: Zydus Lifesciences Ltd. - Business segments
• Exhibit 165: Zydus Lifesciences Ltd. - Key offerings
• Exhibit 166: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 167: Inclusions checklist
• Exhibit 168: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 169: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 170: Research methodology
• Exhibit 171: Validation techniques employed for market sizing
• Exhibit 172: Information sources
• 13.5 List of abbreviations
• Exhibit 173: List of abbreviations